Healthcare · NSE: VIYASH
Viyash Scientific
Q2 FY27 earnings highlights, from the results presentation
Q2 FY27 · From the investor presentation
- M.Cap
- ₹10,439Cr
- P/E
- 44.9×
- 1Y return
- +3.19%
- From 52W high
- −20.7%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 988 | 424 | +133.0% | 946 | +4.4% |
| EBITDA | 165 | 56 | +196.2% | 178 | -7.5% |
| EBITDA margin | 16.7% | 13.1% | +357 bps | 18.9% | -215 bps |
| One-off items | — | -2 | — | — | — |
| PBTProfit before tax | 118 | 27 | +333.3% | 112 | +4.7% |
| Net profit | 76 | 15 | +416.8% | 66 | +15.6% |
| EPS (₹) | 1.69 | 0.58 | +191.4% | 1.47 | +15.0% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
In short
- 01Q2 FY27 revenue was Rs 9,879 Mn, up 16.2% YoY; H1 revenue Rs 19,343 Mn, up 17.8%.
- 02H1 FY27 PAT was INR 164 Cr, up about 50%; adjusted PAT with normalized ESOP cost INR 204 Cr.
- 03Q2 EBITDA before ESOP cost was Rs 2,077 Mn at a 21.0% margin, against 22.1% a year earlier.
- 04Acquisition of BioForLife in Italy was completed on 1 October 2026.
- 05Capex has started on a companion animal tablet facility at Ambernath; slide shows Q1 FY28.
- 06A new 128 KL API block at Nalgonda has received all approvals.
- 07A new oncology finished-dosage R&D centre is being built in Hyderabad.
- 08Net debt stood at Rs 261 Mn.
Capex
Human Health: Building an oncology platform from API to finished dosage, with new R&D centre
Slides · p. 12
Human Health: Building an oncology platform from API to finished dosage, with new R&D centre
“Building an end-to-end oncology platform, from API to finished dosage”
Companion animals: Capex initiated for new companion animal tablet facility at Ambernath
Slides · p. 13
Companion animals: Capex initiated for new companion animal tablet facility at Ambernath
“Capex initiated for new tablet facility Expected commissioning & start of production”
Companion animals: Ambernath companion animal facility: commissioning and start of production expected Q1 FY28
Slides · p. 13
Companion animals: Ambernath companion animal facility: commissioning and start of production expected Q1 FY28
“Commencement Q1 FY28 Capex initiated for new tablet facility Expected commissioning & start of production”
Company investing in new oncology capabilities
Slides · Managing Director and Group CEO · p. 3
Company investing in new oncology capabilities
“We are also investing in new oncology capabilities, in-house”
Companion animals: Ambernath plant to give in-house manufacturing for companion animal pipeline
Slides · p. 13
Companion animals: Ambernath plant to give in-house manufacturing for companion animal pipeline
“Day-1 launch readiness: In-house manufacturing for our companion animal pipeline”
Segments
Formulations: Formulations Q2 FY27 sales Rs 5,587 Mn, up 19% YoY; H1 up 26%
Slides · p. 10
Formulations: Formulations Q2 FY27 sales Rs 5,587 Mn, up 19% YoY; H1 up 26%
“Formulations 5,587 4,687 19% 5,547 1% 11,134 8,858 26%”
Europe: Europe Q2 FY27 sales Rs 1,864 Mn, up 22% YoY
Slides · p. 10
Europe: Europe Q2 FY27 sales Rs 1,864 Mn, up 22% YoY
“Europe 1,864 1,532 22% 1,847 1% 3,711 3,211 16%”
Emerging Markets: Emerging Markets Q2 FY27 sales Rs 2,030 Mn, up 39% YoY
Slides · p. 10
Emerging Markets: Emerging Markets Q2 FY27 sales Rs 2,030 Mn, up 39% YoY
“Emerging Markets 2,030 1,457 39% 2,008 1% 4,038 2,898 39%”
India: India Q2 FY27 sales Rs 504 Mn, up 39% YoY; H1 up 49%
Slides · p. 10
India: India Q2 FY27 sales Rs 504 Mn, up 39% YoY; H1 up 49%
“India 504 362 39% 430 17% 934 625 49%”
USA: USA Q2 FY27 sales Rs 1,189 Mn, down 11% YoY and down 6% QoQ
Slides · p. 10
USA: USA Q2 FY27 sales Rs 1,189 Mn, down 11% YoY and down 6% QoQ
“USA 1,189 1,337 -11% 1,262 -6% 2,451 2,124 15%”
Demand
APIs: New API block adds capacity to support rising demand for select APIs
Slides · p. 14
APIs: New API block adds capacity to support rising demand for select APIs
“New block adds capacity to support rising demand”
Margins and costs
Q2 FY27 EBITDA margin 21.0% vs 22.1% a year ago; H1 21.3% vs 19.3%
Slides · p. 8
Q2 FY27 EBITDA margin 21.0% vs 22.1% a year ago; H1 21.3% vs 19.3%
“% EBITDA 21.0% 22.1% 21.6% 21.3% 19.3%”
Q2 FY27 gross margin 53.7% vs 55.5% a year ago and 54.1% in Q1
Slides · p. 8
Q2 FY27 gross margin 53.7% vs 55.5% a year ago and 54.1% in Q1
“% Gross margin 53.7% 55.5% 54.1% 53.9% 53.8%”
Q2 FY27 ESOP cost Rs 421 Mn vs Rs 100 Mn a year ago; H1 Rs 667 Mn
Slides · p. 8
Q2 FY27 ESOP cost Rs 421 Mn vs Rs 100 Mn a year ago; H1 Rs 667 Mn
“ESOP cost (421) (100) (246) (667) (230)”
Normalized annual ESOP cost assumed at INR 25 Cr
Slides · p. 3
Normalized annual ESOP cost assumed at INR 25 Cr
“Notes: * Assuming normalized annual ESOP cost at INR 25 Cr”
Q2 FY27 depreciation Rs 453 Mn vs Rs 591 Mn a year ago
Slides · p. 8
Q2 FY27 depreciation Rs 453 Mn vs Rs 591 Mn a year ago
“Depreciation (453) (591) (618) (1,071) (1,147)”
Debt and working capital
Net debt Rs 261 Mn at end of Q2 FY27
Slides · p. 5
Net debt Rs 261 Mn at end of Q2 FY27
“Million Million Net Debt- ₹ 261 Mn”
Q2 FY27 finance cost Rs 137 Mn vs Rs 175 Mn a year ago; H1 Rs 262 Mn
Slides · p. 8
Q2 FY27 finance cost Rs 137 Mn vs Rs 175 Mn a year ago; H1 Rs 262 Mn
“Finance Cost (137) (175) (125) (262) (379)”
Net debt was Rs 861 Mn in Q1 FY27
Slides · p. 6
Net debt was Rs 861 Mn in Q1 FY27
“Net Debt - ₹ 861 Mn”
Net debt was Rs 4,095 Mn in H1 FY26
Slides · p. 5
Net debt was Rs 4,095 Mn in H1 FY26
“Net Debt - ₹ 4,095 Mn”
Net debt to LTM EBITDA at 0.0x in Q2 FY27
Slides · p. 6
Net debt to LTM EBITDA at 0.0x in Q2 FY27
“₹9,879 ₹2,077 21.0% 0.0x”
Acquisitions and new business
Companion animals: Acquisition of BioForLife in Italy completed on 1 October 2026
Slides · p. 11
Companion animals: Acquisition of BioForLife in Italy completed on 1 October 2026
“Completion of Acquisition: 1 October 2026”
Companion animals: BioForLife sales force has 85% vet clinic coverage in Italy
Slides · p. 11
Companion animals: BioForLife sales force has 85% vet clinic coverage in Italy
“Italy; salesforce has 85% vet”
Companion animals: BioForLife share purchase agreement signed on 21 July 2026
Slides · p. 11
Companion animals: BioForLife share purchase agreement signed on 21 July 2026
“Execution of SPA: 21 July 2026”
One-offs
Prior-year one-off was a provision for customer claim on earlier shipments
Slides · p. 10
Prior-year one-off was a provision for customer claim on earlier shipments
“*Adjustment on account of hyperinflation in Turkey as per Ind AS 29 # Provision for customer claim on shipments in prior years”
Other
Q2 FY27 revenue Rs 9,879 Mn, up 16.2% YoY; H1 Rs 19,343 Mn, up 17.8%
Slides · p. 8
Q2 FY27 revenue Rs 9,879 Mn, up 16.2% YoY; H1 Rs 19,343 Mn, up 17.8%
“Revenue from Operations 9,879 8,503 16.2% 9,464 4.4% 19,343 16,419 17.8%”
H1 FY27 PAT at INR 164 Cr, up about 50% from last year
Slides · Managing Director and Group CEO · p. 3
H1 FY27 PAT at INR 164 Cr, up about 50% from last year
“profit after tax (PAT) at INR 164 Cr, up ~50% from last year. H1 adjusted PAT with normalized”
H1 adjusted PAT with normalized ESOP cost is INR 204 Cr
Slides · Managing Director and Group CEO · p. 3
H1 adjusted PAT with normalized ESOP cost is INR 204 Cr
“ESOP cost is INR 204 Cr*. The completion of acquisition of BioForLife in Italy strengthens our”
Q2 FY27 EBITDA before ESOP cost Rs 2,077 Mn, up 10.3%; H1 Rs 4,124 Mn, up 29.9%
Slides · p. 8
Q2 FY27 EBITDA before ESOP cost Rs 2,077 Mn, up 10.3%; H1 Rs 4,124 Mn, up 29.9%
“EBITDA¹ 2,077 1,883 10.3% 2,047 1.4% 4,124 3,176 29.9%”
Q2 FY27 earnings after tax Rs 847 Mn, up 16.1%; H1 Rs 1,639 Mn, up 49.4%
Slides · p. 8
Q2 FY27 earnings after tax Rs 847 Mn, up 16.1%; H1 Rs 1,639 Mn, up 49.4%
“Earnings After Tax 847 729 16.1% 793 6.8% 1,639 1,098 49.4%”
Sources
- Investor presentation, Q2 FY27 Filed 13 Nov 2026 · 24 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

